Insiders Trades
Biodesix Inc Stock: price and insider trades · United States
1 insider bought €894k of shares over the last 90 days, the latest filed 13 Aug 2026.
Biodesix Inc: what insiders have been doing
Biodesix Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 35 filings came from 7 insiders.
Both sides are active: 6 purchases worth €2.7M and 5 sales worth €14k, from 1 insider and 5 insiders respectively. On balance, insiders were net buyers of €2.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder. At €804k, the purchase published on 27 January 2026 by Schuler Jack W is the largest of the period.
The latest purchase dates back some time: it was published 65 days ago, on 13 August 2026. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 35 filings, this issuer sits above that mark. Our records for Biodesix Inc go back to 2021, with 59 purchases and 5 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 88.5 m USD and net income at -35.3 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
203
Thresholds
n/a
Buy Volume
€48M
59 ops. · all time
Sell Volume
€13,668
5 ops. · all time
Who traded when
BuySaleJack W. Schuler13 buys
Lawrence T. Kennedy Jr.2 buys
Chris Vazquez1 sale
Gary Anthony Pestano1 sale
Hany Massarany1 buy
John Patience1 buy
+4 other insiders
Since the insiders bought
- -0.0%Entry US$24.00 · Close 14 Oct 2026 US$23.99
- -71.3%Entry US$25.60 · Close at T+365 US$7.34
- -70.9%Entry US$26.60 · Close at T+365 US$7.73
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,031 of 24,148 companies
31.8
score / 100
Value16
Quality48
FCF yld-9.1%
Earn yld-14%
EV/EBITDA·
ROE·
Gross mgn81%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.70
Analyst consensus
6 analysts1.00/5
US$30.00Target US$37.33(+45%)US$41.00
Income statement
RevenueUS$88.5M
Gross profitUS$71.8M81% margin
EBITDA-US$21.9M-25% margin
Net income-US$35.3M-27.0% margin
Valuation
P/Book29.6x
Beta0.55
Balance sheet & cash
Market capUS$271.2M
Total debtUS$72.9M
Free Cash Flow-US$23.7M
Debt / Equity785%
Profitability & ownership
ROE-540.0%
ROA-14.1%
% insiders40.1%
% institutions41.4%
Last declaration on 2 October 2026
Declarations203 total
1,360 sharesCommon StockSEC:0000905148-26-004336:0
15,000 shares@ US$24.46610.12% mcap0.7% of flowCommon StockSEC:0000905148-26-003641:0
Canonical exit: 10 Nov 2026 (T+90)
13,900 shares@ US$24.24670.11% mcap0.6% of flowCommon StockSEC:0000905148-26-003599:0
Canonical exit: 8 Nov 2026 (T+90)
13,700 shares@ US$24.00810.10% mcap0.6% of flowCommon StockSEC:0000905148-26-003599:1
Canonical exit: 9 Nov 2026 (T+90)
1,361 sharesCommon StockSEC:0000905148-26-003146:0
1,361 sharesCommon StockSEC:0000905148-26-001495:0
563 sharesCommon StockSEC:0000905148-26-000990:0
1,469 sharesCommon StockSEC:0000905148-26-000989:0
4,844 sharesCommon StockSEC:0000905148-26-000988:0
1,528 sharesCommon StockSEC:0000905148-26-000987:0
1,469 sharesCommon StockSEC:0000905148-26-000986:0
2,584 sharesCommon StockSEC:0000905148-26-000637:0
263 sharesCommon StockSEC:0000905148-26-000636:0
1,600 sharesCommon StockSEC:0000905148-26-000635:0
1,481 sharesCommon StockSEC:0000905148-26-000634:0
9,998 sharesCommon StockSEC:0000905148-26-000633:0
80,000 shares@ US$11.80841.7% of flowCommon StockSEC:0000905148-26-000362:0
Canonical exit: 23 Apr 2026 (T+90)
20,000 shares@ US$11.80320.4% of flowCommon StockSEC:0000905148-26-000362:1
Canonical exit: 26 Apr 2026 (T+90)
82,465 shares@ US$10.95691.6% of flowCommon StockSEC:0000905148-26-000331:0
Canonical exit: 22 Apr 2026 (T+90)
298 shares@ US$8.14935.4% of flowCommon StockSEC:0000905148-26-000249:1
298 shares@ US$8.149313.0% of flowCommon StockSEC:0000905148-26-000251:1
83 shares@ US$8.149339.0% of flowCommon StockSEC:0000905148-26-000253:1
970 shares@ US$8.14934.1% of flowCommon StockSEC:0000905148-26-000250:1
805 sharesCommon StockSEC:0000905148-26-000249:0
2,633 sharesCommon StockSEC:0000905148-26-000250:0
25 of 203 declarations
About Biodesix Inc
Biodesix, Inc. (ticker BDSX) is a U.S.-based precision diagnostics company listed on the NASDAQ in the United States, with a focused franchise in lung disease and, more specifically, thoracic oncology. Founded in 2006 and headquartered in Louisville, Colorado, Biodesix has built a niche position around clinical decision support in lung cancer and pulmonary nodule management. Its corporate headquarters and primary laboratory are located at 919 W Dillon Road, Louisville, CO 80027.
The company’s business model is centered on two complementary pillars. First, Biodesix commercializes proprietary diagnostic tests, notably under the Nodify Lung and IQLung brands. Nodify Lung is designed to help clinicians assess the malignancy risk of a lung nodule using blood-based biomarkers, supporting earlier and more informed care pathways. IQLung is a treatment-guidance portfolio for patients with non-small cell lung cancer, combining tumor profiling and immune profiling tools. Second, the company provides development services to biopharmaceutical, life sciences, and research customers, leveraging its scientific, technical, and operational capabilities to support diagnostic and therapeutic development programs.
Read moreShow less
From a competitive standpoint, Biodesix operates in a highly specialized but attractive diagnostics market where clinical utility, reimbursement, turnaround time, and integration into physician workflows are critical. The company emphasizes clinically validated tests and a number of Medicare-covered offerings, which supports adoption in a market where evidence and reimbursement are decisive. Its differentiation is rooted in deep expertise in lung disease rather than in a broad, generalist diagnostics platform.
Geographically, the business is primarily U.S.-focused, consistent with its headquarters, commercial footprint, and reimbursement-driven model. Recent company communications indicate improving momentum in 2025, with revenue growth supported by both diagnostic testing and development services. Biodesix has also highlighted new clinical and economic data supporting Nodify Lung, alongside a Thermo Fisher Scientific recognition as a Center of Excellence for NGS diagnostics, which helps reinforce the credibility of its technology platform.
For French-speaking investors, Biodesix is best viewed as a specialized healthcare stock listed on the NASDAQ, with growth potential tied to execution, reimbursement dynamics, and broader adoption of its lung cancer diagnostics portfolio.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
